TORONTO, Apr 21, 2009 (BUSINESS WIRE) -- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced the appointment of Fred Nicklas as Vice-President, U.S. Commercial Operations of BTA Pharmaceuticals, Inc. The appointment is effective May 4, 2009. In his role, Mr. Nicklas will oversee sales, marketing and managed care efforts for BTA's products.
Mr. Nicklas has 20 years of experience in marketing and sales, largely in areas of specialty central nervous system (CNS) disorders. Prior to joining Biovail, Mr. Nicklas was Senior Director, Epilepsy Marketing at Valeant Pharmaceuticals. Prior to that, Fred spent two years as Group Product Director for Keppra (an antiepileptic drug) at UCB Pharmaceuticals and eight years at AstraZeneca, where he was Director of Brand Communications for Seroquel (a drug used to treat schizophrenia and bipolar disorder) and Director of Managed Markets for Nexium. From 1988 to 2003, he successfully held positions of growing responsibility in sales management at Bristol-Myers Squibb and AstraZeneca in a number of specialty areas, including CNS disorders.
Fred holds a Bachelor of Science in Applied Biology and Biopsychology from the Georgia Institute of Technology in Atlanta, Georgia.
About Biovail Corporation
Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at www.biovail.com.
For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to [email protected].
SOURCE: Biovail Corporation
Biovail Corporation
Nelson F. Isabel, (905) 286-3000
Vice-President, Investor Relations and Corporate Communications
